Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
SNN
BuyPremium GrowerSmith & Nephew plc · Healthcare · United Kingdom · $12.1B · Avg Vol: $48M/d
67
StockRankGet insider-trade alerts
Q
68
V
43
M
51
P/E (TTM)
19.6x
ROE
11.9%
D/E
0.7x
Dividend %
1.4%
COMPANY DESCRIPTION
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5.2B | 5.5B | 5.8B | 6.2B | 5.7% | 6.3B | 6.5B | 6.8B | 5.2% |
| EPS | 1.04 | 1.25 | 1.96 | 2.91 | 41.2% | 1.47 | 3.16 | 3.49 | 9.5% |
| Shares | 420.3M | 420.3M | 420.3M | 420.3M | 0.0% | 418.5M | — | — | — |
| Debt | 2.9B | 3.1B | 3.3B | 3.3B | 5.0% | 3.8B | — | — | — |
| Equity | 5.3B | 5.2B | 5.3B | 5.3B | 0.2% | — | — | — | — |
| Op CF | 468.0M | 608.0M | 987.0M | 1.3B | 40.0% | 1.3B | — | — | — |
| Inv CF | -472.0M | -448.0M | -569.0M | -406.0M | — | — | — | — | — |
| Fin CF | -926.0M | -200.0M | -86.0M | -955.0M | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)-15.1%
SMA 50SMA 200
Close
$27.73
RSI (14)
28.9
52W High
$37.90
From 52W High
0.7%
SCORE BREAKDOWN
Quality
68
ROIC
10.8%73.3
ROE
11.9%75.6
GP/Assets
41.2%79.5
Op. Margin
14.5%73.7
FCF/Assets
8.1%81.7
Piotroski
783.9
Int. Cover
5.4x52.4
D/E Ratio
0.73x19.7
Current Ratio
2.14x41.4
Value
43
P/E (TTM)
19.6x60.6
EV/EBITDA
46.6x12.6
P/FCF
14.2x74.6
P/B
11.9x9.9
P/S
1.9x70.0
Div Yield
1.4%38.5
Momentum
51
52W High %
73%55.1
RS 6M
-28%29.7
SMA 50/200
0.95x42.1
EPS Rev 4W
+7.1%86.4
EPS Rev 12W
—N/A
EPS Improve
+66%63.5
Q Growth
3%40.7
FUNDAMENTALS
Market Cap
$12.1B
P/E (Forward)
11.8x
Gross Margin
68.4%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of SNN are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| SNN | Smith & Nephew plc(you) | $12.1B | 67 | Buy |
| LIVN | LivaNova PLC | $4.4B | 83 | Strong Buy |
| NIOX.L | NIOX Group Plc | $387M | 83 | Strong Buy |
| EKF.L | EKF Diagnostics Holdings plc | $147M | 83 | Strong Buy |
| CTEC.L | Convatec Group PLC | $6.0B | 73 | Buy |
| KNSA | Kiniksa Pharmaceuticals International, plc | $6.1B | 79 | Buy |
| GNS.L | Genus plc | $2.1B | 62 | Hold |
| HLN | Haleon plc | $44.5B | 82 | Strong Buy |
| IHC.L | Inspiration Healthcare Group plc | $27M | 48 | Hold |
| HIK.L | Hikma Pharmaceuticals PLC | $4.5B | 94 | Strong Buy |
Peer medians: ROE -4.5% · P/E 25.7x · Gross margin 54.5%